Adcendo
Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.
$75MSeries C
Role not disclosedPV
Pontifax Venture Capital
Activity from announced rounds
Activity in this selectionjens-urbaniak-f719b368
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $75M 1 disclosed · full round size, not this investor’s share